VeriMomБезопасен ли eriodictyol при беременности?
No harmonised CLP classification or SCCS/CIR safety assessment for eriodictyol was identified (ECHA Annex VI/CIR). Peer‑reviewed literature reports biological activity of the flavanone class and some in vitro estrogenic/ER‑modulating activity for flavonoids (PubMed), so a theoretical mechanism (weak endocrine activity) is possible, but there are no in vivo reproductive toxicity or human teratogenicity data specifically for eriodictyol (PubMed, PubChem). Topical systemic absorption is plausible but expected low for typical cosmetic use given the compound’s flavanone structure and polarity (PubChem).
Related ingredients
Frequently asked questions
- Безопасен ли eriodictyol при беременности?
- No harmonised CLP classification or SCCS/CIR safety assessment for eriodictyol was identified (ECHA Annex VI/CIR). Peer‑reviewed literature reports biological activity of the flavanone class and some in vitro estrogenic/ER‑modulating activity for flavonoids (PubMed), so a theoretical mechanism (weak endocrine activity) is possible, but there are no in vivo reproductive toxicity or human teratogenicity data specifically for eriodictyol (PubMed, PubChem). Topical systemic absorption is plausible but expected low for typical cosmetic use given the compound’s flavanone structure and polarity (PubChem).
- Безопасен ли eriodictyol при грудном вскармливании?
- No evidence of reproductive or lactation hazards, no harmonised classification or CIR/SCCS opinion (ECHA Annex VI; CIR). Theoretical endocrine activity based on class/limited in vitro data supports a low mechanistic concern only (PubMed). Systemic exposure after topical application is expected low but measurable, so breastmilk exposure would be low (PubChem; no specific human PK data found).
- Безопасен ли eriodictyol для кожи малыша?
- No infant‑specific toxicity data or harmonised flags (ECHA Annex VI/CIR). Mechanistic concern remains theoretical only (flavonoid class in vitro activity) with no in vivo reproductive/developmental data for eriodictyol (PubMed). Dermal exposure concern is elevated for 0–3 yr due to higher skin permeability and surface‑area‑to‑weight ratio; if adult topical exposure is low but measurable (e=1), infant exposure is increased by +1 per guidance (PubChem, PubMed).
- Как VeriMom оценивает eriodictyol?
- VeriMom оценивает eriodictyol в 87/100 (низкий риск) на основе EU CosIng, классификаций ECHA и исследований PubMed.
- Какие безопасные альтернативы eriodictyol при беременности?
- См. наш список безопасных альтернатив eriodictyol с аналогичной функцией и классификацией без известных рисков.
Проверь любой состав за 2 секунды
Скачай VeriMom бесплатно — отсканируй любой продукт и мгновенно получи оценку безопасности при беременности.
Медицинская оговорка
Данная информация предоставлена исключительно в образовательных целях и не является медицинской рекомендацией. Оценки безопасности основаны на общедоступных данных и могут не отражать все риски. Всегда консультируйтесь с вашим врачом перед использованием любых средств во время беременности или грудного вскармливания.